Table 1.
Demographic findings of the study cohort
| Diagnostic category | n | Female (%) | Age at LP (years) | Time between clinical onset and LP (mos) | Follow-up duration (mos)a | Time between clinical onset and last visit (years) |
|---|---|---|---|---|---|---|
| Definite NP cohort | ||||||
| LB-α-Syn+ | 21 | 9 (42.9) | 75.8 ± 6.3 | 12.2 ± 28.9 | 3.9 ± 8.8 | 2.2 ± 2.5 |
| DLB | 14 | 6 (42.9) | 76.9 ± 5.4 | 17.3 ± 34.1 | 5.0 ± 10.4 | 1.7 ± 2.9 |
| Dementia with incidental LB | 7 | 3 (42.9) | 74.3 ± 7.7 | 2.0 ± 1.8 | 1.1 ± 1.1 | 0.3 ± 0.2 |
| LB-α-Syn− | 101 | 45 (44.5) | 68.5 ± 9.9 | 3.7 ± 13.4 | 4.5 ± 12.2 | 0.7 ± 1.8 |
| AD | 17 | 9 (52.9) | 76.4 ± 7.5 | 1.6 ± 2.5 | 1.9 ± 2.6 | 0.3 ± 0.3 |
| PSP | 1 | 0 (0) | 64 | 108 | 30 | 11.5 |
| MSA | 2 | 1 (50.0) | 62.5 ± 7.8 | 40.5 ± 54.4 | 68.5 ± 28.9 | 9.1 ± 2.1 |
| Syn− controlsb | 81 | 35 (43.2) | 66.9 ± 9.9 | 1.9 ± 2.1 | 3.2 ± 7.6 | 0.4 ± 0.7 |
| Clinical cohort | ||||||
| DLB | 34 | 9 (26.5) | 73.2 ± 7.5 | 78.8 ± 105.8 | 14.9 ± 21.4 | 7.8 ± 8.7 |
| AD | 43 | 22 (52.2) | 66.3 ± 7.8 | 43.4 ± 39.7 | 12.7 ± 15.8 | 4.7 ± 3.5 |
| PSP/CBS | 30 | 19 (63.3) | 70.7 ± 6.7 | 47.0 ± 32.9 | 8.9 ± 15.0 | 4.7 ± 2.8 |
| MSA | 31 | 12 (38.7) | 60.7 ± 8.6 | 55.2 ± 42.0 | 23.4 ± 16.3 | 6.4 ± 3.6 |
| PDc | 71 | 19 (26.8) | 62.2 ± 8.8 | 56.8 ± 45.8 | 31.6 ± 35.9 | 7.4 ± 4.2 |
| PAF | 28 | 11 (39.3) | 65.5 ± 8.5 | 119.3 ± 62.5 | 43.9 ± 50.4 | 13.6 ± 6.9 |
| iRBD | 18 | 6 (33.3) | 68.2 ± 7.7 | 71.5 ± 60.7 | 10.6 ± 15.1 | 6.9 ± 4.7 |
| Clinical controlsd | 62 | 30 (48.4) | 53.9 ± 15.4 | 158.7 ± 152.5 | 30.2 ± 27.5 | 15.5 ± 13.5 |
| Total | 439 | 182 (41.5) | 65.3 ± 11.4 | 59.6 ± 85.6 | 18.3 ± 27.6 | 6.5 ± 7.5 |
LP lumbar puncture, DLB dementia with Lewy bodies, AD Alzheimer’s disease, PD Parkinson’s disease, PSP progressive supranuclear palsy, CBS corticobasal syndrome, MSA multiple system atrophy, PAF pure autonomic failure, iRBD isolated REM sleep behaviour disorder, α-Syn α-synuclein
aThe follow-up duration was calculated from LP to the last visit (or death)
bNeuropathological cases diagnosed as Creutzfeldt–Jakob disease (n = 51), malignancy (n = 3), vascular disease (n = 6), encephalitis (n = 10), Wernicke’s encephalopathy (n = 3), frontotemporal lobar degeneration plus amyotrophic lateral sclerosis (n = 1), non-specified tauopathy (n = 1), and dementia lacking distinctive pathology (n = 6)
c53 clinically established and 18 probable cases
dFor a detailed list, see Supplementary Table 1 (online resource)